E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is testing the use E-B-FAHF-2 Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to safely tolerate food allergens. Specifically in this protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat. Omalizumab is considered an investigational drug for the treatment of food allergies in children and adults. Investigational means it has not been approved by the Food and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness (which is the ability to consume a food allergen and pass an oral food challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely ingest the foods they are allergic to.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

E-B-FAHF-2, Multi OIT and Xolair for Food Allergy

NCT06103656

Food Allergy

COMPLETED PHASE2

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

NCT01781637

Peanut Allergy Food Allergy

COMPLETED PHASE1/PHASE2

Omalizumab in the Treatment of Peanut Allergy

NCT00949078

Food Allergy Peanut Allergy

COMPLETED PHASE2

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696

Peanut Allergy Multi-food Allergy

COMPLETED PHASE3

The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge

NCT01003301

Cat Allergy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prior studies have shown that this Chinese herbal formulation is safe and well-tolerated in food allergic individuals. While oral immunotherapy (OIT) can lead to desensitization, it remains uncertain whether this treatment can lead to lasting protection. Therefore, this study aims to use the Chinese herbal formula in combination with OIT to determine whether sustained protection can be achieved. All subjects will receive multi-allergen OIT, along with a 4 month course of omalizumab to provide added safety for the initial dose escalation and build up phases. Subjects will be randomized to receive active Chinese herbal formula or placebo. Subjects will be treated with OIT for 2 years and then food challenges will be performed to assess for desensitization. For those who achieve desensitization, all treatments will be discontinued and food challenges will be performed 3 months later to assess for sustained unresponsiveness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Food Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chinese Herbal Medication

Group Type ACTIVE_COMPARATOR

Chinese Herbal Medication

Intervention Type DRUG

Capsules, 26 month course, starting 2 months pre-OIT

Omalizumab

Intervention Type DRUG

4 months course, starting 2 months pre-OIT through the 2 month build-up phase

Multi OIT

Intervention Type DRUG

24 months of multi OIT (maintenance dose of 1gm each food allergen)

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT

Omalizumab

Intervention Type DRUG

4 months course, starting 2 months pre-OIT through the 2 month build-up phase

Multi OIT

Intervention Type DRUG

24 months of multi OIT (maintenance dose of 1gm each food allergen)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chinese Herbal Medication

Capsules, 26 month course, starting 2 months pre-OIT

Intervention Type DRUG

Placebo

Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT

Intervention Type DRUG

Omalizumab

4 months course, starting 2 months pre-OIT through the 2 month build-up phase

Intervention Type DRUG

Multi OIT

24 months of multi OIT (maintenance dose of 1gm each food allergen)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

E-B-FAHF-2 Placebo Chinese Herb Xolair®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 6 through 40 years
* At least one of the following for each of the 3 study allergens: serum IgE \>4 kU/L or skin prick test \>6mm
* dose limiting symptoms at a cumulative dose of \<=444 mg protein for 3 allergens as screening double-blind, placebo-controlled food challenge
* use of an effective method of contraception by females of child-bearing potential
* ability to ingest oat or corn with no allergic reaction

Exclusion Criteria

* If baked milk or egg are tolerated (assessed by clinical report), then milk or egg may not be included as a study allergen
* Any disorder in which epinephrine is contraindicated such as coronary artery disease, uncontrolled hypertension, and serious ventricular arrhythmias
* History of other chronic disease requiring therapy (other than asthma, atopic dermatitis, or rhinitis)
* History of eosinophilic gastrointestinal disease
* Current participation in any other interventional study
* Investigational drug use within 90 days
* Subject is on build-up phase of any allergen immunotherapy (prior to maintenance dosing)
* Current uncontrolled moderate to severe asthma as defined by:

* FEV1 value \<80% predicted (or PFR if unable to perform spirometry) or any clinical features of moderate or severe persistent asthma baseline severity (as defined by the 2007 NHLBI Guidelines) and greater than high daily doses of inhaled corticosteroids (as defined for children and adults using dosing tables from the 2007 NHLBI Guidelines).
* Use of steroid medications in the following manners: history of daily oral steroid dosing for \>1 month during the past year, having 1 burst or steroid course within the past 6 months, or having \>1 burst oral steroid course within the past 12 months.
* Asthma requiring \>1 hospitalization in the past year for asthma or \>1 ED visit in the past 6 months for asthma.
* Use of systemic steroid medications (IV, IM or oral) for indications other than asthma for \> 3 weeks within the past 6 months
* Inability to discontinue antihistamines for the initial day of escalation, skin testing or DBPCFC
* Use of Xolair® (omalizumab) within the past 6 months
* Known sensitivity to Xolair® (omalizumab) or to the class of study drugs
* Body weight more than 90 kg, or subjects with weight-IgE combination that yields a dose requirement greater than 600 mg dosing
* Use of beta-blockers (oral), (ACE) inhibitors, angiotensin-receptor blockers or calcium channel blockers
* Pregnancy or lactation
* Inability to swallow placebo capsules
* Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements

Minimum Eligible Age

6 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No